MSB 15.2% $1.33 mesoblast limited

Cell Therapy News/Articles, page-17542

  1. 326 Posts.
    lightbulb Created with Sketch. 365
    Thanks Phaedrus - the stats are very instructive in potentially demonstrating the regulator’s blind spot. It’s an interesting angle.

    Perhaps the numbers could be reproduced and framed in terms of a question to Dr. Klinker. I noticed a while back that he went straight from interning at the FDA while doing his PhD to a permanent role - yes he may have a lot of research experience, but if you pop that question and steer him towards a reality check, he might look at the numbers staring at him and start thinking about what institutional bias there might be. (I say that because I have the same worry about my son who’s gone straight from
    fininishing his PhD to a pure research job.) The answer could be as simple or mundane as their adoption of the popular contempt towards a dodgy stem cell industry that has escaped regulatory scrutiny for a very long time. Sometimes it’s just useful to be able to look at things with different lenses.


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.33
Change
0.175(15.2%)
Mkt cap ! $1.341B
Open High Low Value Volume
$1.15 $1.33 $1.15 $20.78M 16.57M

Buyers (Bids)

No. Vol. Price($)
19 126151 $1.33
 

Sellers (Offers)

Price($) Vol. No.
$1.33 36285 6
View Market Depth
Last trade - 15.35pm 23/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.